Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Assets (2016 - 2025)

Lineage Cell Therapeutics' Assets history spans 16 years, with the latest figure at $112.6 million for Q4 2025.

  • For Q4 2025, Assets fell 0.56% year-over-year to $112.6 million; the TTM value through Dec 2025 reached $112.6 million, down 0.56%, while the annual FY2025 figure was $112.6 million, 0.56% down from the prior year.
  • Assets reached $112.6 million in Q4 2025 per LCTX's latest filing, up from $89.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $174.5 million in Q4 2021 to a low of $89.6 million in Q3 2025.
  • Average Assets over 5 years is $118.1 million, with a median of $112.9 million recorded in 2023.
  • Peak YoY movement for Assets: skyrocketed 61.69% in 2021, then dropped 29.15% in 2022.
  • A 5-year view of Assets shows it stood at $174.5 million in 2021, then decreased by 29.15% to $123.7 million in 2022, then fell by 18.31% to $101.0 million in 2023, then increased by 12.08% to $113.2 million in 2024, then decreased by 0.56% to $112.6 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Assets are $112.6 million (Q4 2025), $89.6 million (Q3 2025), and $90.8 million (Q2 2025).